Long-Term Therapy With Adefovir Dipivoxil For Hbeag Positive Chronic Hepatitis B Patients With Various Baseline Biochemical Levels: Results From 4 Years Adefovir Dipivoxil Treatment
lei zhuang,jianlan you,leopold kong,y l li,hongbo lei,y l ma,h y chen,h e liu,xiaojun feng,shao jian ma,j h huang,y h che,q q wang,lixian chen,s m yan
DOI: https://doi.org/10.1016/j.ijid.2014.03.1080
IF: 12.073
2014-01-01
International Journal of Infectious Diseases
Abstract:Background: Since the introduction of nucleos(t)ide analogues (NUCs), there has been marked improvement in the care of the patients with chronic hepatitis B, resulting in increased survival. Adefovir dipivoxil (ADV) has shown efficacy and safety in a broad range of populations with chronic hepatitis B over 48 to 96 weeks. This study reports the 192-week long-term efficacy data with ADV treatment in nucleoside-naive HBeAg-positive chronic hepatitis B. Methods & Materials: Ninety-eight HBeAg-positive patients who had never received nucleoside treatment received 192-week ADV10 mg/d therapy. All patients had serum level of HBV load over 105copies/ml and increased serum alanine aminotransferase (ALT) level. Based on serum ALT levels at baseline, all patients were divided into two groups, A (48 patients with serum ALT level less than 200U/L) and B (50 patients with ALT level more than 200U/L). Serum HBV load was measured with quantitative real-time-PCR. ALT activity, HBeAg, anti-HBe-antibodies, HBVDNA level in serum were evaluated at baseline, week 12, 24, 48, 72, 96, 144, 168 and 192 and during therapy. Results: After 24 weeks of therapy, mean reduction of HBVDNA level, the percentage of patients with HBVDNA lower than 5 log10 copies/ml and the percentage of patients with HBVDNA level decrease of more than 2 log10 copies/ml in group B were significantly higher than those in group A (P < 0.05, respectively). At the end of 24, 48, 96, 144 and 192 weeks, the patients in group B had higher rates of undetectable serum HBVDNA levels and ALT normalization than those in group A (46% vs 25%, 74% vs 54.2%, 88% vs 70.8%, 90% vs 72.9%, 91.3% vs 71.8%; 52% vs 31.3%, 66% vs 43.8%, 82% vs 62.5%, 88% vs 66.7%, 93.8% vs72.5%; P < 0.05, respectively). HBeAg seroconversion rate was significant hihger in group B than those in group A(P < 0.05). There was no evidence of adverse effect in patients treated for up to 192 weeks. Conclusion: Adefovir dipivoxil is an effective treatment option for nucleoside-naive patients with HBeAg-positive chronic hepatitis B, especially for those with high serum ALT levels at baseline. Adefovir dipivoxil treatment through 192 weeks was well tolerated and resulted in continued benefit for patients with HBeAg-positive chronic hepatitis B.